MedDataX Logo

Single-Dose COMP360 Psilocybin Shows Clinical Benefit in Phase 3 TRD Trial

New COMP006 phase 3 data shows single-dose COMP360 psilocybin achieved a 3.8-point MADRS reduction in treatment-resistant depression, with results comparable to esketamine pivotal trials and rapid onset of effect.

New COMP006 phase 3 data shows a 3.8-point MADRS reduction with single-dose COMP360 psilocybin in treatment-resistant depression (TRD). The results are comparable to esketamine pivotal trials in TRD.

COMP360 showed rapid onset of effect in the phase 3 trial. The treatment is administered as a single dose.

Related Articles

Compass Pathways' Psilocybin Drug Succeeds in Second Phase III Trial for Treatment-Resistant Depression

Feb 18, 2026

Compass Pathways Achieves Primary Endpoint in Second Phase 3 Trial of Psilocybin for Depression

Feb 17, 2026

Compass Pathways Reports Positive Phase 3 Data for Psilocybin Depression Treatment

Feb 16, 2026

Compass Pathways Reports Second Positive Phase 3 Trial for Psilocybin in Depression

Feb 17, 2026

Compass Pathways Achieves Second Positive Phase 3 Trial for Psilocybin Depression Treatment

Feb 16, 2026

References

  1. The Challenge of Concentrated Insulin and Micro-Dosing - HCPLive · hcplive.com
  2. Early Gut Bacteria Suppress Allergen-Specific IgE Without Affecting IgG | HCPLive · hcplive.com
  3. Single-Dose COMP360 Psilocybin Shows Clinical Benefit in Phase 3 TRD Trial | HCPLive · hcplive.com
Back to News